Skip to content

Venture

LOGO 8-01

Affiliations

New York University

Technologies

Therapeutic

Indication

Oncology

Personalized Medicine

TEZCAT is developing a biologics-based therapeutic approach to treat mutant Ras cancers, such as colorectal cancer.

 

TEZCAT team:

CEO – Alex Efron
CSO – Craig Ramirez, Ph.D.
Ops. Mgr – Andy Hauser, Ph.D.